FILE:CELG/CELG-8K-20070103161007.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	Financial Statements and Exhibits
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2006 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-16132 22-2711928 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.) 86 Morris Avenue, Summit, New Jersey 07901 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 -------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On January 2, 2007, Celgene Corporation announced that its Board of Directors elected Sol J. Barer, Ph.D., Chief Executive Officer, to the additional position of Chairman of the Board, effective immediately. John W. Jackson, Chairman of the Board, retired from that position and as a member of the Board of Directors on December 31, 2006. Attached hereto as Exhibit 99.1 is the Press Release announcing such action. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 Press Release dated January 2, 2007 announcing the election of Sol J. Barer, Ph.D., Chief Executive Officer, to the additional position of Chairman of the Board, effective immediately. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELGENE CORPORATION Date: January 3, 2007 By: /s/ David W. Gryska ------------------------------------- Name: David W. Gryska Title: Chief Financial Officer
EXHIBIT INDEX Exhibit No. Description - ----------- ----------- 99.1 Press Release dated January 2, 2007 announcing the election of Sol J. Barer, Ph.D., Chief Executive Officer, to the additional position of Chairman of the Board, effective immediately.

Exhibit 99.1 Contact: Robert J. Hugin Brian P. Gill President and Vice President, Chief Operating Officer Corporate Communications Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 CELGENE CORPORATION ELECTS SOL J. BARER, PH.D. TO CHAIRMAN OF THE BOARD SUMMIT, N.J. - (JANUARY 2, 2007) - CELGENE CORPORATION (NYSE: CELG) announced that its Board of Directors elected Sol J. Barer, Ph.D., Chief Executive Officer, to the additional position of Chairman of the Board, effective immediately. Dr. Barer has been our Chief Executive Officer since May 1, 2006, one of our Directors since March 1994, and is a member of the Executive Committee of our Board of Directors. Dr. Barer served as President from October 1993 to May 1, 2006, and our Chief Operating Officer from March 1994 to May 1, 2006. John W. Jackson, Chairman of the Board, retired from that position on December 31, 2006. Mr. Jackson served as our Chairman of the Board since January 1996 and as the Chairman of the Executive Committee of our Board of Directors. Mr. Jackson served as Chief Executive Officer from January 1996 to May 1, 2006. "In 2006, Sol led Celgene to another record performance," said John W. Jackson. "Under Sol's leadership the company has delivered outstanding results across all areas of our business and for our shareholders. Celgene has strong global leadership in place and is strategically positioned to maximize its global potential." Jack Bowman, Lead Director of the Celgene Board of Directors said, "The Board has been impressed with Sol's leadership skills and strategic vision that will lead Celgene to the next level of growth. We are particularly pleased with the smooth transition of executive responsibilities executed this year. The Board recognizes and greatly appreciates John's extraordinary contributions to Celgene. The growth and performance of the Company during his tenure was unparalleled. He leveraged his strong entrepreneurial spirit with sound business acumen to build this Company into an established leader in the global biopharmaceutical industry." ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WHICH ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND OTHER FACTORS DESCRIBED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS OUR 10K, 10Q AND 8K REPORTS. # # #


